Filing Flows › Vistagen Therapeutics (VTGN) › R&D spending
Vistagen Therapeutics (VTGN) R&D spending by quarter
Vistagen Therapeutics' R&D spending was $10.9M in Q1 FY27 (first quarter fiscal 2027), -16% from Q4 FY26. Over the last 6 quarters it ranged from $10.9M (Q1 FY27) to $15.9M (Q2 FY26).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 FY27 | $10.9M | -16% | -7% |
| Q4 FY26 | $13.1M | -8% | — |
| Q3 FY26 | $14.2M | -11% | +26% |
| Q2 FY26 | $15.9M | +36% | — |
| Q1 FY26 | $11.7M | +3% | — |
| Q3 FY25 | $11.3M | — | — |
Q1 FY27 at a glance
Vistagen Therapeutics, Q1 FY27: revenue $1.5M (+505% year over year), operating margin -904.3%, net loss $13.0M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vistagen Therapeutics' R&D spending?
Vistagen Therapeutics' R&D spending was $10.9M in Q1 FY27 (first quarter fiscal 2027), -16% from Q4 FY26.
How has Vistagen Therapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $10.9M (Q1 FY27) to $15.9M (Q2 FY26).